Intellia Therapeutics Q3 net loss widens 26% to $127.49 million
NTLA•Intellia Therapeutics’ third-quarter 2026 net loss widened 26% year over year to $127.49 million, while collaboration revenue fell 48% to $7.16 million. The company had $614.8 million in cash, cash equivalents and marketable securities at September 30, and said existing resources are expected to fund operations into at least 2028.
1. Quarterly results
Intellia Therapeutics’ third-quarter 2026 net loss widened 26% year over year to $127.49 million. Collaboration revenue fell 48% to $7.16 million, primarily due to lower revenue from Regeneron.
2. Cash and product timing
Cash, cash equivalents and marketable securities totaled $614.8 million at September 30, with existing resources expected to fund operations into at least 2028. Lonvo-z faces a March 10, 2027 FDA decision, and the company plans a commercial launch in the first quarter of 2027.
